Algeta ASA: Net Sales of Xofigo for Third Quarter 2013

            Algeta ASA: Net Sales of Xofigo for Third Quarter 2013

Not intended for US media

Oslo, Norway, 31 October 2013 - Algeta ASA (OSE: ALGETA), a company focused on
the development of novel targeted  cancer therapeutics, announces that  Bayer, 
in its third quarter 2013 results presented today, disclosed that US net sales
for Xofigo (radium Ra  223 dichloride) during the  period amounted to  EUR12m 

As previously  announced, Algeta  will report  third quarter  2013 results  on 
Wednesday, 6 November 2013.  A presentation by  members of Algeta's  executive 
management team to investors, analysts and  the press will take place in  Oslo 
at 10:00 CET. Algeta will also host an international conference call at  14:30 
CET/08:30 Eastern Time.

About Radium Ra 223 Dichloride

Radium Ra  223  dichloride  (radium-223)  is currently  not  approved  by  the 
European Medicines Agency  (EMA) or  other authorities outside  the US.  Bayer 
submitted a Marketing Authorisation Application  to the EMA for radium-223  in 
December 2012 and subsequently in other territories.

Radium-223 (as Xofigo^®  injection) is approved  in the United  States and  is 
indicated for  the treatment  of patients  with castration-resistant  prostate 
cancer (CRPC), symptomatic  bone metastases and  no known visceral  metastatic 

Radium  Ra  223   dichloride  (radium-223)  is   an  alpha   particle-emitting 
pharmaceutical. Its active moiety mimics calcium and selectively targets bone,
specifically areas  of bone  metastases, by  forming complexes  with the  bone 
mineral hydroxyapatite. The high linear energy transfer of alpha emitters  (80 
keV/micrometer) leads  to a  high  frequency of  double-strand DNA  breaks  in 
adjacent tumour  cells, resulting  in a  potent cytotoxic  effect.  Additional 
effects on the tumour  microenvironment including osteoblasts and  osteoclasts 
also contribute  to  the in  vivo  efficacy.  The alpha  particle  range  from 
radium-223 is less than  100 micrometers (less than  10 cell diameters)  which 
minimises damage to the surrounding normal tissue.

In September 2009, Algeta signed an  agreement with Bayer for the  development 
and commercialization of radium-223. Under  the terms of the agreement,  Bayer 
will develop, apply for health authority approvals worldwide and commercialize
Xofigo globally.  Algeta is  eligible for  royalties and  milestones based  on 
Bayer's sales of  Xofigo outside the  US, and Algeta  US, LLC is  co-promoting 
Xofigo with Bayer in the US.


Xofigo^® is a registered trademark of Bayer AG

For further information, please contact:

Mike Booth                         +1 646 410 1884
Communications & Corporate Affairs
Media enquiries:
Mark Swallow                       +44 207 638 9571
Citigate Dewe Rogerson   
Knut Ekern                         +47 22 04 82 00
Gambit Hill & Knowlton   
Investor enquiries:
Tricia Truehart                    +1 646 378 2953
The Trout Group          

About Algeta

Algeta is a company focused  on developing, manufacturing and marketing  novel 
targeted therapies for patients with  cancer. The Company is headquartered  in 
Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge,  MA 
performing commercial marketing operations in the US. Algeta is listed on  the 
Oslo Stock  Exchange  (Ticker:  ALGETA). For  more  information  please  visit

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Press release


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Algeta ASA via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.